文献速递结核与非结核分枝杆菌

沙利度胺治疗儿童复杂性中枢神经系统结核:观察性队列研究启示

Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该回顾性队列纳入38例连续接受沙利度胺辅助治疗的中枢神经系统结核相关并发症患儿,疗程按并发症类型为1.0至3.9个月不等。37例获得满意的临床和影像学应答,未观察到皮疹、肝炎、血液学异常或腿痛性痉挛。沙利度胺在该人群安全、耐受良好且似有临床疗效。

要点

  • 沙利度胺辅助治疗儿童CNS结核并发症,37/38例临床和影像学应答满意。
  • 未观察到皮疹、肝炎、血液学异常或腿痛性痉挛等不良反应。
  • 疗程因并发症类型而异:结核瘤中位3.9个月,视神经炎2.0个月,EPC 1.0个月。

核心结论

  • 沙利度胺辅助治疗儿童CNS结核相关并发症安全、耐受良好且似有临床疗效。
  • 这是目前成人或儿童中应用沙利度胺辅助治疗CNS结核相关并发症的最大队列。

研究设计与样本

  • 回顾性队列研究,纳入10年间连续接受沙利度胺辅助治疗的38例CNS结核相关并发症患儿。

主要发现

  • 最常见首发症状为局灶性运动障碍(n=16),其次为颅神经麻痹和小脑功能障碍。
  • 3例表现为癫痫部分性持续状态(EPC),4例因视交叉蛛网膜炎致盲,2例因脊髓结核瘤致截瘫。
  • 37/38例患儿获得满意的临床和影像学应答。
  • 未观察到皮疹、肝炎、血液学异常或腿痛性痉挛。

关键数值与推荐

  • 沙利度胺辅助治疗剂量为3-5 mg/kg/day。
  • 结核瘤患儿中位疗程3.9个月(IQR 2.0-5.0个月)。
  • 视神经炎患儿中位疗程2.0个月(IQR 1.3-7.3个月)。
  • EPC患儿中位疗程1.0个月(IQR 1-2.5个月)。

临床怎么用

  • 对CNS结核相关并发症患儿,可考虑沙利度胺作为辅助免疫调节治疗。
  • 疗程应根据并发症类型个体化确定。

局限性

  • 回顾性观察性队列设计,样本量38例,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Much of the neurological sequelae of central nervous system (CNS) tuberculosis (TB) is due to an excessive cytokine-driven host-inflammatory response. Adjunctive corticosteroids, which reduce cytokine production and thus dampen the inflammation, improve overall survival but do not prevent morbidity. This has prompted investigation of more targeted immunomodulatory agents, including thalidomide. METHODS: We describe a retrospective cohort of 38 children consecutively treated with adjunctive thalidomide for CNS TB-related complications over a 10-year period. RESULTS: The most common presenting symptom was focal motor deficit (n = 16), followed by cranial nerve palsies and cerebellar dysfunction. Three of the 38 children presented with large dural-based lesions, manifesting as epilepsia partialis continua (EPC), 4 presented with blindness secondary to optochiasmatic arachnoiditis, and 2 children developed paraplegia due to spinal cord TB mass lesions. Duration of adjunctive thalidomide therapy (3-5 mg/kg/day) varied according to complication type. In children compromised by TB mass lesions, the median treatment duration was 3.9 months (interquartile range [IQR], 2.0-5.0 months), whereas in children with optic neuritis it was 2.0 months (IQR, 1.3-7.3 months) and in EPC it was 1.0 months (IQR, 1-2.5 months). Satisfactory clinical and radiological response was observed in 37 of the children. None of the children experienced rashes, hepatitis, or hematologic derangements or complained of leg cramps. CONCLUSIONS: This study is the largest cohort of adult or pediatric patients treated with adjunctive thalidomide for CNS TB-related complications. The drug has proved to be safe and well tolerated and appears to be clinically efficacious. The potential role of thalidomide or analogues in the treatment of other tuberculous meningitis-related complications requires further exploration.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. van Toorn R, Solomons RS, Seddon JA, et al. Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort. Clin Infect Dis. 2021. PMID: 33283220. doi:10.1093/cid/ciaa1826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。